Cited by 377Lipid metabolism and disordersLipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Graham, Mark J., Lee, Richard G., Bell, Thomas A., Fu, Wuxia, Mullick, Adam E., Alexander, Veronica J., Singleton, Walter, Viney, Nick, Geary, Richard, Su, John, Baker, Brenda F., Burkey, Jennifer, Crooke, Stanley T., Crooke, Rosanne M.·2013·Circulation Research

DOI 10.1161/circresaha.111.300367

Open this paper in CoChat — free account

Abstract

Rationale: Elevated plasma triglyceride levels have been recognized as a risk factor for the development of coronary heart disease. Apolipoprotein C-III (apoC-III) represents both an independent risk factor and a key regulatory factor of plasma triglyceride concentrations. Furthermore, elevated apoC-III levels have been associated with metabolic syndrome and type 2 diabetes mellitus. To date, no selective apoC-III therapeutic agent has been evaluated in the clinic. Objective: To test the hypothesis that selective inhibition of apoC-III with antisense drugs in preclinical models and in healthy volunteers would reduce plasma apoC-III and triglyceride levels. Methods and Results: Rodent- and human-specific second-generation antisense oligonucleotides were identified and evaluated in preclinical models, including rats, mice, human apoC-III transgenic mice, and nonhuman primates. We demonstrated the selective reduction of both apoC-III and triglyceride in all preclinical pharmacological evaluations. We also showed that inhibition of apoC-III was well tolerated and not associated with increased liver triglyceride deposition or hepatotoxicity. A double-blind, placebo-controlled, phase I clinical study was performed in healthy subjects. Administration of the human apoC-III antisense drug resulted in dose-dependent reductions in plasma apoC-III, concomitant lowering of triglyceride levels, and produced no clinically meaningful signals in the safety evaluations. Conclusions: Antisense inhibition of apoC-III in preclinical models and in a phase I clinical trial with healthy subjects produced potent, selective reductions in plasma apoC-III and triglyceride, 2 known risk factors for cardiovascular disease. This compelling pharmacological profile supports further clinical investigations in hypertriglyceridemic subjects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circresaha.111.300367

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Ethical principles for medical research involving human subjects
Eckstein, S. (2003) · Cambridge University Press eBooks · doi:10.1017/cbo9780511550089.027 · Cited by 2,592
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
Available, N. (2000) · JAMA · doi:10.1001/jama.284.23.3043 · Cited by 2,344
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Lipoprotein lipase: from gene to obesity
Wang, H., & Eckel, R. H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90920.2008 · Cited by 741
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts
Carr, T. P., Andresen, C. J., & Rudel, L. L. (1993) · Clinical Biochemistry · doi:10.1016/0009-9120(93)90015-x · Cited by 558
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia
Johansen, C. T., Wang, J., Lanktree, M. B., Cao, H., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., et al. (2010) · Nature Genetics · doi:10.1038/ng.628 · Cited by 437

Flagged first, then by citations

Show all 71 references

1 of the 71 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

10.1194/jlr.M900346-JLR200 · DOI

Sorted by citations

Items 301–377 of 377

Hypertriglyceridemia as a multidisciplinary problem of modern medicine
Васильевна, Ц. О., Ozhiganova, N. V., Kastalap, V. V., Саяровна, Б. С., & Latyntseva, L. D. (2020) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2020-9-4-114-123 · Cited by 5
Discovery of Novel APOC3 Isoforms in Hepatic and Intestinal Cell Models Using Long-Read RNA Sequencing
Farstad-O’Halloran, K., Sooda, A., Iqbal, T., Wilton, S. D., & Aung-Htut, M. T. (2025) · Genes · doi:10.3390/genes16040412 · Cited by 3
Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials
Ballantyne, C. M., Baass, A. W., Rosenson, R. S., Hegele, R. A., Nicholls, S. J., Vasas, S., Clifton, P. M., Lucas, K. J., Páll, D., Zhou, R., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101523 · Cited by 3
Antisense therapies for cardiovascular/metabolic diseases
Geary, R. S., Crooke, R. M., Bhanot, S., & Singleton, W. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2013.06.001 · Cited by 3
Self-citation
Reduced high density lipoprotein cholesterol in severe hypertriglyceridemic ApoCIII transgenic mice via lowered hepatic ApoAI synthesis
Han, Y., Qi, R., & Liu, C. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.147 · Cited by 3
ADME: Assessing Pharmacokinetic–Pharmacodynamic Parameters of Oligonucleotides
Jansson‐Löfmark, R., Ahlström, C., & Gennemark, P. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9670-4_19 · Cited by 3
The forkhead box O family in insulin action and lipid metabolism
Lee, S., Zhu, C., Yamauchi, J., Zhu, P., Feng, X., Qu, S., & Dong, H. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00013-0 · Cited by 3
Apoliprotein C-III (Apo C-III) inhibitors effect of antisense oligonucleotides in the management of dyslipidemia
Sasmana, I. G. A. P., Rahadi, P. N. K., Devy, A. A. T., Dewi, P. A. S., Supadmanaba, I. G. P., & Wihandani, D. M. (2023) · Indonesia Journal of Biomedical Science · doi:10.15562/ijbs.v17i1.455 · Cited by 3
IMPACT OF CARDIOVASCULAR RISK GENES POLYMORPHISM IN THE DEVELOPMENT OF METABOLIC DISORDERS IN PERSONS EXPOSED TO VINYL CHLORIDE
Валерьевна, К. И., Dyakovich, O. A., Katamanova, E. V., & Ещина, И. М. (2019) · Hygiene and Sanitation · doi:10.18821/0016-9900-2019-98-10-1113-1118 · Cited by 3
High-Density Lipoproteins
Darabi, M., Zakiev, E., & Kontush, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_18 · Cited by 3
Antisense Oligonucleotide Targeting Sortilin Reduces Vascular Calcification in Mice in a Sex-Dependent Manner
Lupieri, A., BECKER-GREENE, D. R., Le, T.-D., Roschel, M. M., Jha, P. K., Sonawane, A. R., Mullick, A. E., Tsimikas, S., Kuraoka, S., Singh, S. A., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321999 · Cited by 2
Self-citation
The Approval of Redemplo for Familial Chylomicronemia Syndrome and the Many Flavors of GalNAc-Oligonucleotides
Alterman, J. F., Gross, K. Y., & Khvorova, A. (2026) · Nucleic Acid Therapeutics · doi:10.1177/21593337261435980 · Cited by 2
Twenty-five years of statins: where do we go from here?
Gotto, A. M., & Moon, J. E. (2015) · Clinical Lipidology · doi:10.2217/clp.14.62 · Cited by 2
Synthesis of LNA gapmers that replace a phosphorothioate linkage with a sulfonamide in the gap region, and their ability to form duplexes with complementary RNA targets
Seio, K., Ohnishi, R., Tachibana, S., Mikagi, H., & MASAKI, Y. (2024) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob01350f · Cited by 2
Lipid nanocarriers for RNA and DNA therapeutics: Next-generation delivery strategies in precision medicine
Moon, S., & Lee, J. B. (2025) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2025.08.042 · Cited by 2
Complexity, cost, and content – three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing
Nedelkov, D., & Hu, Y.-M. (2019) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm-2019-0977 · Cited by 3
Genetische Analysen als Basis einer individualisierten Medizin bei koronarer Herzkrankheit
Kessler, T., Kaess, B. M., Bourier, F. J., Erdmann, J., & Schunkert, H. (2014) · Herz · doi:10.1007/s00059-013-4048-z · Cited by 2
Association of Apolipoprotein C3 Levels and Hepatic Steatosis: A Follow-Up Study
Heinz, P., Boehm, B. O., Schmidberger, J., Kratzer, W., & for the EMIL-Study Group (2020) · Hormone and Metabolic Research · doi:10.1055/a-1116-2333 · Cited by 2
Technical appendix to locally stationary wavelet fields with application to the modelling and analysis of image texture.
Eckley, I. A., Nason, G. P., & Treloar, R. L. (2009) · Lancaster EPrints (Lancaster University) · Cited by 2
Rola samorzadu terytorialnego w rozwoju lokalnym
Parysek, J. J. (1995) · Studia. Polska Akademia Nauk. Komitet Przestrzennego Zagospodarowania Kraju · Cited by 2
Gene Therapy
Shahryari, A., Nazari, Z., Jazi, M. S., Hashemi-Shahraki, F., Wißmiller, K., Xu, W., Burtscher, I., & Lickert, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00213-9 · Cited by 2
Special Patient Populations
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
Circulation Research “In This Issue” Anthology
Williams, R. R. E., & Editors, T. (2017) · Circulation Research · doi:10.1161/res.0000000000000152 · Cited by 2
Enzymes | Lipoprotein Lipase
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00125-0 · Cited by 2
Small Dense Low-Density Lipoprotein: Biomarker or Potential Drug Target?
Samanta, B. (2019) · Annals of the National Academy of Medical Sciences (India) · doi:10.1055/s-0039-1697239 · Cited by 1
Antisense Oligonucleotide Therapeutics Targeting Age-Related Diseases
Lee, H. G., Kim, J., Jang, C., & Shin, M. (2026) · BioDrugs · doi:10.1007/s40259-025-00761-x · Cited by 1
A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques
Fukase, T., & Dohi, T. (2026) · npj Cardiovascular Health · doi:10.1038/s44325-026-00104-x · Cited by 2
Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome
Man, Z., Asano, S., Kakutani, T., Kiyoshi, A., Hino, K., & Ikeda, A. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102930 · Cited by 1
Hypertriglyceridemia in an outpatient department – Significance as an atherosclerotic risk factor
Scholz, M., Tselmin, S., Fischer, S., & Julius, U. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.011 · Cited by 2
Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease: a case–control and meta-analysis study
Yang, G., Lei, M.-M., Yu, C.-L., Liu, X.-X., An, Z., & Song, C.-L. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0110-6 · Cited by 1
Lipids in Coronary Heart Disease
Martin, S. S., Joshi, P. H., & Michos, E. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00007-3 · Cited by 2
Ersonified diagnostic and correction dyslipidemia approach by profiling of apolipoproteins
Kachkovsky, M. A., Vvedenskaya, I. P., Vvedensky, V. Y., Supilnikov, A. A., Ponomareva, J. V., & Milyakova, M. N. (2020) · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) · doi:10.20340/vmi-rvz.2020.4.11 · Cited by 1
Personalized Therapy of Cardiovascular Disorders
Jain, K. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-62080-6_13 · Cited by 1
Special Patient Populations
Reyes‐Soffer, G., & Ginsberg, H. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00035-9 · Cited by 1
Advances in Hypercholesterolemia
Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 1
CLINICAL BIOCHEMISTRY METHODS IN OBJECTIVE EVALUATION OF OVEREATING FOOD OF CARNIVORES (MEAT) BY A PHYLOGENETICALLY HERBIVOROUS HOMO SAPIENS (A PATIENT)
Titov, V. N., Ta, R., Ивановна, К. В., & Alchinova, I. B. (2019) · Russian Clinical Laboratory Diagnostics · doi:10.18821/0869-2084-2019-64-1-4-13 · Cited by 1
Síndrome de Quilomicronemia Familiar: Algoritmo Diagnóstico
Colaco, I. B., Araújo, F., Aguiar, P., Cruz, D., Bourbon, M., Duarte, J. S., & Veríssimo, M. T. (2021) · Medicina Interna · doi:10.24950/rspmi.r.92.4.2021 · Cited by 1
Isotopic Tracers for the Measurement of Metabolic Flux Rates
Beysen, C., Angel, T. E., Hellerstein, M. K., & Turner, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_9 · Cited by 2
RNA therapies for cardiovascular disease
Laina, A., Vlachogiannis, N. I., Stamatelopoulos, K. S., & Stellos, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822546-2.00003-4 · Cited by 2
Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals
Reyes‐Soffer, G., & Ginsberg, H. N. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch17
Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy
Kataoka, Y., & Nicholls, S. J. (2014) · Journal of the Japanese Coronary Association · doi:10.7793/jcoron.20.033
Hypertriglyceridemia: the future of genetics to guide individualized therapeutic strategies
Moens, S. J. B., Hassing, C., Nieuwdorp, M., Stroes, E. S. G., & Dallinga‐Thie, G. M. (2013) · Clinical Lipidology · doi:10.2217/clp.13.23
HDL as a Biomarker of Rejection in Heart Transplant
Altieri, P. I. (2014) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/2455-8583.000001
Srce i krvni Sudovi
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Biomarker des Lipoproteinstoffwechsels
von Eckardstein, A. (2015) · Cardiovascular Medicine · doi:10.4414/cvm.2015.00297
Dissecting the role of apolipoprotein CIII in diabetic wound healing
Cho, M. M. W. (2019) · doi:10.32657/10220/48515
Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis
Ward, N. C., & Watts, G. F. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_33
Dislipidemias: terapêutica atual e perspectivas futuras na redução de riscos cardiovasculares
Lopes, M. G., & Sposito, A. C. (2018) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2018.17.3.19-23
Lipid-Lowering Drugs
Rye, K., & Barter, P. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_6075
Lipid-Lowering Drugs
Rye, K., & Barter, P. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_6075-1
Therapy and clinical trials
Elkin, R. L., & Krasuski, R. A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000151
Biomarkers of Cardiovascular Disorders
Jain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7431-3_15
Prognostic Impact of Remnant-like Particle Cholesterol in Patients with Differing Glucose Metabolic Status: an Observational Cohort Study from ChinaPreprint
Zhao, Q., Zhang, T.-Y., Cheng, Y.-J., Ma, Y., Xu, Y.-K., Yang, J.-Q., & Zhou, Y.-J. (2020) · doi:10.21203/rs.3.rs-33302/v1
Circulation Research “In This Issue” Anthology
Williams, R. M., & Editors, T. (2014) · Circulation Research · doi:10.1161/res.0000000000000042
Is apoCIII-Lowering A Double-Edged Sword?
Tang, X., Zhou, H., Yan, H., Niimi, M., & Fan, J. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.le002
Cardiovascular Diseases and their Novel Therapeutic Interventions: A Literature Review
Prajapati, K. B. (2022) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.408
Evolving Therapeutic Targets
Hussain, A., & Ballantyne, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00028-5
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Bobik, A., Cohen, N. D., Jenkins, A. J., Kyaw, T. S., SULLIVAN, D. R., Wu, X., Yu, X.-Y., & Little, P. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_30
Application of Framework Nucleic Acid‐Based Nanomaterials in the Treatment of Endocrine and Metabolic Diseases
Xiao, J. (2024) · Wiley eBooks · doi:10.1002/9783527841912.ch8
Recent advances in the medicinal chemistry of antisense oligonucleotides
Ito, K. R., Uda, K., & Obika, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00031-5
Apolipoproteins and cardiovascular diseases
Kaur, A., Saha, S., Ujjainiya, R., Ray, A., Basak, T., & Sengupta, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19116-9.00032-4
Additional file 1 of The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes
Yexuan, C., Zhang, H.-W., Jin, J.-L., Liu, H.-H., Zhang, Y., Gao, Y., Guo, Y.-L., Wu, N.-Q., Hua, Q., Li, Y.-F., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12618338
Additional file 2 of Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Figshare · doi:10.6084/m9.figshare.12401108
Additional file 1 of Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Figshare · doi:10.6084/m9.figshare.12401099
Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials
Masood, A., Qureshi, A. U. H., Khalid, Z., Shahid, H., Malik, A. R. K., Javed, S., Mandahar, M., Amanullah, A., Siddiqui, Y., Anwar, T., et al. (2026) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2026.3543
Apolipoprotéine C3 : élément essentiel du métabolisme lipidique et nouvelle cible thérapeutique
Akkoura, L., & Vergès, B. L. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.009
Progress and Prospects of APOC3-Targeted siRNA Drugs in Coronary Artery Disease Research
黄, 林. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1631183
Effets des différentes techniques de chirurgie bariatrique sur le métabolisme des lipoprotéines riches en triglycérides(LRT) intestinales et hépatiques chez le patient obèse
Padilla, N. (2014) · theses.fr (ABES) · doi:10.70675/d0d25e1ez35f7z44f5z8ed8z8283dae28540
Omics of human plasma lipoproteins : role in cardiometabolic diseases
Zakiev, E. (2019) · theses.fr (ABES) · doi:10.70675/d80fee25za2f2z4790z9eb9ze82d5514a198
RNA-Based Therapeutics
Mustafa, A., Irfan, T., Babar, M. M., & Rajadas, J. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_24
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Fusogenic RNA Nanomodules for Fusion‐Mediated and Multiplexed siRNA Delivery
Moon, S., Jang, I., Kim, T., Yoon, N., Yum, K., & Lee, J. B. (2026) · Advanced Functional Materials · doi:10.1002/adfm.77032
Olezarsen for hypertriglyceridemia and familial chylomicronemia syndrome: A Next-generation APOC3-targeted RNA therapy
Sharma, J., Jain, M., & Rathore, J. S. (2026) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_62_25
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_5
Olezarsen for the Treatment of Hypertriglyceridemia
Rodriguez, A. S. H., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_6
Apolipoprotein CIII as a therapeutic target in obesity-associated metabolic dysfunction
Valladolid‐Acebes, I., Berggren, P., & Juntti‐Berggren, L. (2026) · Advances in Biological Regulation · doi:10.1016/j.jbior.2026.101183
Pharmacotherapy for MASLD/MASH: approved therapies, drug repurposing, and emerging mechanism-based candidates
Syed‐Abdul, M. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2749643

Authors: Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., Baker, B. F., Burkey, J., Crooke, S. T., & Crooke, R. M.
Affiliations: Ionis Pharmaceuticals (United States) (US)
Corresponding author: Graham, Mark J.
Lee, Richard G.
ORCID: Lee, Richard G.
Mullick, Adam E.
Alexander, Veronica J.
Geary, Richard
Baker, Brenda F.
Crooke, Stanley T.
Venue: Circulation Research
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2013-05-24
Volume: 112
Issue: 11
Pages: 1479-1490
ISSN: 0009-7330 (ISSN-L)
1524-4571
DOI: 10.1161/circresaha.111.300367
OpenAlex: W2170210469
Cited by: 377
References: 71
Citations by year: 2026: 16 · 2025: 14 · 2024: 15 · 2023: 17 · 2022: 31 · 2021: 19 · 2020: 41 · 2019: 31 · 2018: 29 · 2017: 25 · 2016: 45 · 2015: 41 · 2014: 39 · 2013: 12
FWCI: 31.05
Type: journal article
Language: en
Open access: closed
Locations: Circulation Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: apolipoprotein C-III, antisense oligonucleotides, plasma triglycerides, hypertriglyceridemia, triglyceride-lowering therapy, cardiovascular risk factors, type 2 diabetes, metabolic syndrome, hepatotoxicity, non-human primates
MeSH terms: Animals, Double-Blind Method, Humans, Macaca fascicularis, Macaca mulatta, Mice, Inbred C57BL, Oligonucleotides, Placebos, Rats, Zucker, Receptors, LDL, Risk Factors, RNA, Messenger, Triglycerides, Hypertriglyceridemia, Genetic Therapy, Oligonucleotides, Antisense, Mice, Knockout, Mice, Rats, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks